Diem Nguyen has more than 25 years of experience and extensive expertise in the pharmaceutical industry. She is currently the CEO of Xalud Therapeutics, a clinical stage non-viral gene therapy biotechnology company. Prior to Xalud, she served as Executive Vice President of Biopharma for PPD, Inc. a leading global clinical research organization. Dr. Nguyen joined PPD from Pfizer in 2018, where she served as Global President, Americas, Pfizer Essential Health and Global Sterile Injectables, responsible for commercial businesses in the U.S., Latin America, Canada and Puerto Rico. In that role, she had P&L responsibility with more than $11 billion in annual revenues and commercial responsibilities across multiple therapeutic areas in solid oral drugs, sterile injectables, biosimilars and devices, overseeing over 5,000 Pfizer employees. She also led commercial development for the Sterile Injectables business, actively leading efforts in Pfizer’s acquisition and integration of Hospira, to create a leading business with $6 billion in global revenues.
Dr. Nguyen currently serves on the board of Verrica Pharmaceuticals, Vitara, and Children’s Hospital of Philadelphia. She earned a bachelor’s degree in Chemistry and a Ph.D. in Biochemistry and Molecular Genetics at the University of Virginia, as well as an M.B.A. from UVA’s Darden Graduate School of Business Administration.